Full Breakdown
Promising Alzheimer’s Prevention Found in Anti-Seizure Drug Levetiracetam
3/4/2026, 1:41:37 AM
Breakthrough Findings on Levetiracetam
A recent study conducted by researchers at Northwestern University has identified the anti-seizure medication levetiracetam as a potential preventive treatment for Alzheimer’s disease. Originally approved by the FDA in November 1999 for treating partial-onset seizures, levetiracetam has shown effectiveness in preventing the formation of toxic amyloid beta peptides, which are associated with Alzheimer’s pathology. The study, published in *Science Translational Medicine*, demonstrated that levetiracetam inhibited the production of amyloid-beta 42 in both animal models and cultured human neurons, as well as in post-mortem brain tissue from individuals with Down syndrome, who are at a higher risk for developing Alzheimer’s.
Mechanism of Action and Implications
Jeffrey Savas, the study's corresponding author and associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, emphasized that while existing Alzheimer’s medications like lecanemab and donanemab focus on clearing existing amyloid plaques, levetiracetam targets the production of amyloid-beta 42 peptides. Savas noted that the brain's ability to prevent the formation of these toxic proteins diminishes with age, leading to the development of Alzheimer’s. For levetiracetam to be effective as a preventive measure, it must be administered to high-risk individuals up to 20 years before any elevated amyloid-beta levels are detected.
Observational Data and Future Research
The researchers also analyzed previous clinical data, finding that Alzheimer’s patients taking levetiracetam experienced a "significant delay" in cognitive decline compared to those not on the medication. Although the observed changes were modest, Savas indicated that this supports the drug's potential to slow Alzheimer’s progression. Future research aims to recruit individuals with genetic forms of Alzheimer’s for further testing.
Limitations and Side Effects
Despite the promising findings, the study has limitations, including its reliance on animal models and cultured cells without direct human trials. The observational nature of the study means it cannot definitively prove causation between levetiracetam and the prevention of toxic brain proteins. Savas cautioned that the medication is not without drawbacks; it metabolizes quickly in the body, and the research team is working on developing a more effective version. Common side effects of levetiracetam include drowsiness, dizziness, and potential mood changes, with rare but serious risks such as severe allergic reactions and suicidal ideation.
Official Statements & Responses
Funding for this study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund. The researchers continue to explore the drug's efficacy and safety, aiming to refine its application for Alzheimer's prevention.
Criticism & Opposition
While the findings are promising, some experts may express caution regarding the reliance on animal models and the lack of human trials. Critics may argue that more robust clinical studies are necessary to validate the drug's effectiveness and safety in preventing Alzheimer’s.
Verbatim Quotes
“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid-beta 42 peptides and amyloid plaques,” — Jeffrey Savas, Associate Professor of Behavioral Neurology
“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” — Jeffrey Savas, Associate Professor of Behavioral Neurology
“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.” — Jeffrey Savas, Associate Professor of Behavioral Neurology
